Drug Interactions between landiolol and sparsentan

Consumer information for this interaction is not currently available.

MONITOR: Concomitant use of sparsentan and antihypertensive drugs or drugs with hypotensive properties may result in additive blood pressure-lowering effects. Sparsentan is an endothelin and angiotensin II receptor antagonist. Hypotension has been observed in patients treated with angiotensin II receptor antagonists (ARBs) and endothelin receptor antagonists (ERAs) and was observed in clinical studies with sparsentan. In PROTECT, the randomized, double-blind, active-controlled clinical study in adults with primary immunoglobulin A nephropathy (IgAN), there was a greater incidence of significant hypotension-related adverse events, including orthostatic hypotension and dizziness in those treated with sparsentan compared to irbesartan.

MANAGEMENT: Caution and monitoring for hypotension and appropriate volume status is recommended if sparsentan is used in combination with antihypertensive medication or other medication with hypotensive effects. A dosage reduction or discontinuation of concomitant antihypertensive therapy should also be considered in patients at risk for hypotension. If hypotension develops despite dose reduction or cessation of concomitant antihypertensive therapy, a dose reduction or dose interruption of sparsentan should be considered. If the hypotensive response is transient, sparsentan may be administered once blood pressure has stabilized. Patients should be advised to contact their physician if they experience symptoms of hypotension such as dizziness, lightheadedness, or fainting.